TO: All persons and entities who purchased or otherwise acquired the publicly traded common stock of Mylan N.V. ("Mylan") from February 16, 2016 through May 7, 2019, inclusive (the "Settlement Class ...

Clears way for shareholder meeting on whether Southpointe generic pharmaceutical giant will proceed with takeover of Perrigo. Teva Pharmaceutical Industries on Monday ended its hostile bid for Mylan ...

Add Yahoo as a preferred source to see more of our stories on Google. A file photo showing the EpiPen auto-injection epinephrine pens manufactured by Mylan NV pharmaceutical company are seen in ...

Drugmaker Mylan has started selling a generic version of its emergency allergy treatment EpiPen at half the price of the branded option, the cost of which drew national scorn and attracted ...

Mylan NV said on Thursday, Aug. 25, it would reduce the out-of-pocket cost of its severe allergy treatment EpiPen through a discount program, a day after Democratic Presidential candidate Hillary ...

Mylan N.V. and Mylan Inc. (Nasdaq: MYL) today announced the successful completion of the acquisition of Abbott Laboratories' (NYSE: ABT) non-U.S. developed markets specialty and branded generics ...

TEL AVIV, Oct 27 (Reuters) - The chief executive of Irish-based generic drugmaker Perrigo Co on Tuesday urged shareholders not to accept rival Mylan NV's $25 billion hostile bid for the company. Sign ...

(Reuters) - U.S. regulators said on Wednesday that Mylan NV's EpiPen products are in shortage due to manufacturing delays that are creating intermittent supply constraints of the emergency allergy ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. So what: According ...

The drug company that makes the EpiPen says it isn't nearly as profitable as many people assume it is. At least that's the message Mylan NV CEO Heather Bresch will try to deliver to members of ...

Mylan NV has been hit with a new proposed class action lawsuit over the price of its EpiPen allergy treatment, which shot up to more than $600 for a two-pack of the device from less than $100 in 2007.